ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2016
Reimbursable drug classes and ceilings in Italy: why not only one?
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Differential Adherence to Free and Single-Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real-World Analysis in Italy.Advances in therapy · 2024Article
- Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria.Frontiers in public health · 2022Article
- Beyond price: the effects of non-financial barriers on access to drugs and health outcomes.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Article
- Do European pharmacists really have to trespass on medicine?The European journal of health economics : HEPAC : health economics in prevention and care · 2021Article
- Community and hospital pharmacists in Europe: encroaching on medicine?Internal and emergency medicine · 2021Article
- Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario.Frontiers in pharmacology · 2020Article
- Pharmaceutical pricing conundrum: time to get rid of it?The European journal of health economics : HEPAC : health economics in prevention and care · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27255742What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.